|
[1]
|
Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy[J].J Nucl Med, 2000, 41(10):1704-1713. |
|
[2]
|
Slooter GD, Mearadji A, Breeman WA, et al. Somatostatin receptor imaging, therapy and new strategies in patient with neuroendocrine tumours[J]. Br J Surg, 2001, 88(1):31-40. |
|
[3]
|
Chiti A, Briganti V, Fanti S, et al. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours[J]. Q J Nucl Med, 2000, 44(1):42-49. |
|
[4]
|
Kurtaran A, Ofluoglu S, Traub T, et al.An unusual visualization of the gallbladder by somatostatin receptor (SSTR) scintigraphy:usefulness of hepatobiliary imaging for differential diagnosis[J]. Am J Gastroenterol, 2000,95(5):1367-1368. |
|
[5]
|
Forssell-Aronsson EB, Nilsson O, Bejegard SA, et al.111In-DTPA-D-Phel-octreotide binding and somatostatin recoptor subtypes in thyroid tumors[J]. J Nucl Med,2000,41(4):636-642. |
|
[6]
|
Breeman WA,Hofland LJ,van der Phuijm M,et al.A new adiolabelled somatostatin analogue[111In-DTPA-D-Phe1] RC-160:preparation, biological activity, receptor scintigraphy in rats and comparison with[111In-DTPA-D-Phe1] octreotide[J]. Eur J Nucl Med, 1994, 21(4):328-335. |
|
[7]
|
Ander CJ,Dehdashti F,Cctler PD, et al.64Cu-TETA-octreotide as a PET imaging agent for patiengs with neuroendocrine tumor[J]. J Nucl Med,2001,42(20):213-221. |
|
[8]
|
Bakker WH, Breeman WA, van der Pluijm ME, et al. Iodine-131 labelled octreotide:not an option for somatostatin receptor therapy[J]. Eur J Nucl Med, 1996, 23(7):775-781. |
|
[9]
|
Krenning EP, Valkema R, Kooij PP, et al. The role of radioactive somatostatin and its analogues in the control oftumor growth[J]. Recent Results Cancer Res, 2000, 153:1-13. |
|
[10]
|
BugaJ JE, Erion JL, Johnson MA, et al. Radiothapeutic efficacy of (153) Sm-CMBTPA-Tyr(3)-octreotate in tumor-bearing rats * (1)[J]. Nucl Med Biol, 2001, 28(3):327-334. |
|
[11]
|
Liste James J, Moyer BR, Dean T, et al. Small peptides radiolabeled with 99Tcm[J]. Q J Nucl Med, 1996, 40(3):221-233. |
|
[12]
|
Lister-James J, Moyer BR, Dean T. Pharmacokinetic considerations in the development of peptide-basedimaging agents[J]. Q J Nucl Med. 1997,41(2):111-118. |
|
[13]
|
Decristoforo C, Mather S J, et al, Preparation, 99Tem-labeling, and in vitro characteization of HYNIC and N3S modified RC-160 and[Tyr3] octreotide[J]. Bioconjug Chem, 1999, 10(3):144-150. |
|
[14]
|
Kolan H, Li J, Thakur ML. Sandostatin labeled with 99Tcm:in vitro stability, in vivo validity and comparisonwith 111In-DTPA-octreotide[J].Pept Res, 1996, 9(3):144-150. |
|
[15]
|
Bangard M, Behe M, Guhlke S, et al. Detection of somatostatin receptor-positive tumours using the new 99Tcm-tricine-HY-NIC-D-Phe1-Tyr3-octreotide:first results in patientsandcomparison with 111In-DTPA-D-Phel-Tyr3-octreotide:first results in patients and comparison with 111In-DTPA-D-Phel-octretide[J]. Eur J Nucl Med, 2000, 27(6):628-637. |
|
[16]
|
Spradau TW, Edwards WB, Anderson CJ, et al. Synthesis and biologcal evaluation of Tc-99m-cyclopentadienyltricarbon-bonyltechnetium-labeled octreotide[J]. Nucl Med Biol, 199926(1):1-7. |
点击查看大图
下载: